Mesalazine Teva (Mesalazine)

Mesalazine acts locally in the colon to inhibit cyclooxygenase and lipoxygenase enzymes, decreasing prostaglandin and leukotriene production. It also modulates immune cell activity and cytokine release, which together lower mucosal inflammation and promote healing of the intestinal lining.

The dose of Mesalazine Teva is individualized by the prescribing clinician based on disease severity, location, and patient-specific factors. The healthcare professional determines the appropriate strength, frequency, and duration of therapy for each patient.

Safety data for mesalazine in pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss treatment options with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team then replies with pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Mesalazine belongs to the 5‑ASA class, offering a topical anti‑inflammatory effect in the gut. Compared with sulfasalazine, it has fewer systemic side effects because it does not contain a sulfapyridine moiety. Biologic agents provide systemic immunosuppression and are typically reserved for moderate‑to‑severe disease when 5‑ASA therapy is insufficient.

Mesalazine Teva tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in damp or excessively hot environments.

Mesalazine Teva is taken orally as a tablet. It may be swallowed with a glass of water, with or without food, according to the prescribing clinician’s instructions. Consistent timing each day helps maintain stable drug levels in the colon.

Serious adverse events, although rare, include acute pancreatitis, severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, blood dyscrasias (e.g., neutropenia), hepatotoxicity, interstitial nephritis, and severe colitis or intestinal perforation. Patients should seek immediate medical attention if they experience symptoms such as severe abdominal pain, jaundice, rash, or unexplained fever.

Mesalazine Teva is contraindicated in individuals with a known hypersensitivity to mesalazine or any other 5‑ASA compounds. Patients with severe renal impairment, active severe liver disease, or those who have experienced a serious reaction to a similar medication should avoid its use. The prescribing clinician will assess suitability on a case‑by‑case basis.